Table 1 Demographics and clinical history of children with epilepsy based on cannabis extract use history using valid percentage.
From: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community
Currently or have previously used | Never used | Total | |
|---|---|---|---|
N (%) | N (%) | N (%) | |
Number of participants | 41 | 24 | 65 |
Female | 23 (56%) | 14 (58%) | 37 (57%) |
Child’s schooling | |||
Mainstream | 17 (42%) | 10 (42%) | 27 (42%) |
Special education | 16 (39%) | 8 (33%) | 24 (37%) |
Unable to attend school | 8 (19%) | 6 (25%) | 14 (22%) |
Epilepsy aetiology | |||
Unknown | 23 (56%) | 21 (88%) | 44 (68%) |
Genetic | 15 (37%) | 7 (29%) | 22 (34%) |
Structural-metabolic | 3 (7%) | — | 3 (4%) |
*Positive mutation | 12 (29%) | 5 (21%) | 17 (26%) |
SCN1A | 6 | ||
DNM1 | 2 | ||
SCN2A | 1 | ||
PCDH19 | 1 | ||
SCN9A | 1 | ||
Trisomy 16 | 1 | ||
17p13.3 microdeletion | 1 | ||
TSC2 | 1 | ||
Mutation on C5 and C17 | 1 | ||
C.316 C > T | 1 | ||
KCNQ2 | 1 | ||
Drug-resistant epilepsy | 35 (85%) | 12 (50%) | 47 (72%) |
Status epilepticus episodes | 31 (76%) | 14 (58%) | 45 (69%) |
AEDs perceived efficacy | |||
<50% reduction | 26 (63%) | 5 (21%) | 31 (48%) |
≥50% reduction | 15 (37%) | 17 (71%) | 32 (49%) |
Never started | 1 (2%) | 1 (4%) | 2 (3%) |
Mean (SD) | Mean (SD) | Mean (SD) | |
Age of child (years) | 8.9 (4.7) | 8.6 (4.6) | 8.8 (4.6) |
Age at seizure onset (years) | 2.8 (3.7) | 4.2 (4.1) | 3.3 (3.9) |
Number of current AED(s) | 2 (1.3) | 2 (0.9) | 2 (1.2) |
Number of past AED(s) tried | 7.6 (6.8) | 3.6 (5.6) | 6.1 (6.6) |
